STOCK TITAN

Sera Prognostics, Inc. Stock Price, News & Analysis

SERA Nasdaq

Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.

Sera Prognostics, Inc. (SERA) delivers innovative diagnostic solutions for pregnancy complications through advanced biomarker technology. This news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones shaping maternal health diagnostics.

Access authoritative reporting on SERA's progress in precision medicine, including trial results for preterm birth prediction tests and collaborations with leading research institutions. Our curated news collection simplifies tracking of material events influencing the company's position in the $50B+ prenatal diagnostics market.

Key updates include FDA submissions for novel tests, peer-reviewed study publications, and commercial expansion initiatives. All content undergoes rigorous fact-checking to ensure compliance with financial disclosure standards while maintaining clinical accuracy.

Bookmark this page for real-time alerts on earnings announcements, intellectual property developments, and leadership changes. Stay informed about SERA's contributions to reducing neonatal complications through early intervention strategies validated by clinical evidence.

Rhea-AI Summary

Sera Prognostics, known as The Pregnancy Company, will be added to the NASDAQ Biotechnology Index effective December 20, 2021. This inclusion underscores Sera's commitment to enhancing maternal and neonatal health through innovative pregnancy biomarker information. The Nasdaq Biotechnology Index tracks securities in the biotech and pharmaceutical sectors, requiring companies to meet stringent criteria such as market capitalization and trading volume. Sera's PreTRM® test provides early risk assessments for preterm birth, which affects over 10% of U.S. births annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
none
-
Rhea-AI Summary

Sera Prognostics Inc. (NASDAQ: SERA) announced that the Centers for Medicare & Medicaid Services (CMS) has established a Medicare payment rate of $750.00 for the PreTRM® test under the Proprietary Laboratory Analysis code 0247U. This rate will take effect on January 1, 2022, and applies for CY 2022. While this pricing reinforces the test's value, Medicare coverage is not guaranteed. The company aims to negotiate broader insurance coverage to enhance patient access to this innovative test, which predicts the risk of spontaneous preterm birth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA), focused on maternal and neonatal health, announced the publication of a study funded by the Bill & Melinda Gates Foundation in partnership with AMANHI. This study validates the predictive performance of the IBP4/SHBG biomarker pair for spontaneous preterm birth (sPTB) in low and middle-income regions. Conducted on 10,001 pregnant women in Bangladesh, Pakistan, and Tanzania, results confirm that the biomarkers predict sPTB effectively, enhancing the potential for broader application outside of the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
Rhea-AI Summary

Sera Prognostics Inc. (NASDAQ: SERA) announced the appointment of Sandra A. J. Lawrence to its Board of Directors. Ms. Lawrence brings extensive leadership experience and insights from her roles in public and private boards, as well as her tenure as CFO at Children’s Mercy Hospital. The company aims to leverage her expertise to enhance maternal and neonatal health and drive long-term revenue growth. Sera Prognostics specializes in innovative pregnancy biomarker solutions, particularly its PreTRM® test, which aims to predict preterm birth risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
management
-
Rhea-AI Summary

Sera Prognostics Inc. (Nasdaq: SERA) reported a significant revenue increase for Q3 2021, achieving $23,000 compared to $5,000 in Q3 2020. Operating expenses rose to $9.5 million from $4.6 million, primarily due to expanded sales operations and public company costs. R&D spending increased to $2.7 million, reflecting heightened clinical study efforts. The company faced a net loss of $9.9 million, up from $5.1 million year-over-year. Sera continues to see early payer revenues for its PreTRM® test, emphasizing its commitment to improving maternal and neonatal health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Summary

Sera Prognostics, Inc. (NASDAQ: SERA) announced the appointment of Zhenya Lindgardt to its Board of Directors, effective immediately. Lindgardt, with extensive experience in healthcare and technology, aims to enhance the company's mission to improve maternal and neonatal health. Currently the CEO of The Commons Project Foundation, she has also held significant positions at Uber Technologies and The Boston Consulting Group. CEO Gregory C. Critchfield expressed enthusiasm about Lindgardt’s contributions towards innovative solutions for pregnancy-related challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
management
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) has appointed Woodrow Myers, M.D., M.B.A., as an advisor for public and political affairs. Dr. Myers will spearhead initiatives addressing health equity and disparities during pregnancy, a significant focus for the company. Gregory C. Critchfield, CEO, emphasized Dr. Myers' leadership experience in healthcare management and quality initiatives. Sera Prognostics aims to enhance maternal and neonatal health through innovative diagnostic tests like the PreTRM®, which predicts preterm birth risk, thereby enabling timely interventions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
management
-
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) announced the publication of a rigorous validation for its PreTRM® test, identifying a clinical decision point at a 15% risk for spontaneous preterm birth (sPTB). The findings, from the PAPR and TREETOP studies involving over 10,000 subjects, indicate that patients at or above this threshold face significantly higher risks, including severe neonatal morbidity. This validation supports the clinical utility of the PreTRM® test in proactive maternal care, potentially improving pregnancy outcomes and reducing healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) announced a partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families to support families affected by preterm birth. This collaboration aims to address healthcare disparities, particularly among African Americans, who are 50% more likely to experience premature delivery. The initiative includes distributing a children's book, Will Our Egg Hatch Early?, focusing on preterm birth risks. Sera's PreTRM® test offers early risk prediction for preterm births, enhancing proactive prenatal care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) will report its third quarter 2021 financial results on November 9, 2021, after market close. This announcement includes a conference call at 5:00 p.m. ET for discussing operational highlights and financial results. Sera Prognostics specializes in improving maternal and neonatal health through innovative pregnancy biomarker information, notably its PreTRM® test, which predicts preterm birth risk. The company aims to enhance healthcare while reducing costs through early intervention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
conferences earnings

FAQ

What is the current stock price of Sera Prognostics (SERA)?

The current stock price of Sera Prognostics (SERA) is $3.23 as of August 29, 2025.

What is the market cap of Sera Prognostics (SERA)?

The market cap of Sera Prognostics (SERA) is approximately 108.1M.
Sera Prognostics, Inc.

Nasdaq:SERA

SERA Rankings

SERA Stock Data

108.10M
32.84M
10.87%
64.98%
3.27%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY